Cognition Therapeutics Inc (NASDAQ:CGTX) price on Thursday, December 26, rose 18.43% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.77.
A look at the stock’s price movement, the close in the last trading session was $0.65, moving within a range at $0.6521 and $0.79. The beta value (5-Year monthly) was 1.335. Turning to its 52-week performance, $2.95 and $0.34 were the 52-week high and 52-week low respectively. Overall, CGTX moved 88.55% over the past month.
Cognition Therapeutics Inc’s market cap currently stands at around $31.88 million, with investors looking forward to this quarter’s earnings report slated for in January.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CGTX is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend CGTX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CGTX’s current price about 54.84% and 55.19% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 76.77, while 7-day volatility ratio is 16.26% and 17.20% in the 30-day chart. Further, Cognition Therapeutics Inc (CGTX) has a beta value of 1.19, and an average true range (ATR) of 0.10.
If we refocus on Cognition Therapeutics Inc (NASDAQ:CGTX), historical trading data shows that trading volumes averaged 34.3 over the past 10 days and 6.78 million over the past 3 months. The company’s latest data on shares outstanding shows there are 40.81 million shares.
The 15.24% of Cognition Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 10.36% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.82 million on 2024-10-31, giving us a short ratio of 1.07. The data shows that as of 2024-10-31 short interest in Cognition Therapeutics Inc (CGTX) stood at 294.0 of shares outstanding, with shares short rising to 0.53 million registered in 2024-09-30. Current price change has pushed the stock -58.52% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CGTX stock continues to rise going into the next quarter.
